SCHEMBL25753460

SCHEMBL25753460

Cc1ncsc1C(=O)/C=C/c1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.51
MAPT P10636 9/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
LMNA P02545 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
MAPK1 P28482 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HTT P42858 2/20 0.50
PKM P14618 1/20 0.50
KMT2A Q03164 6/20 0.49
MEN1 O00255 4/20 0.49
HSP90AA1 P07900 2/20 0.49
HPGD P15428 2/20 0.48
ABCG2 Q9UNQ0 5/20 0.47
CYP1A1 P04798 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
AHR P35869 1/20 0.47
CYP1B1 Q16678 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25753452 0.82 MAPT (0.57) MAOBMAPTLMNANPC1RAB9A
SCHEMBL25753449 0.80 MAPT (0.57) MAOBMAPTSMN1; SMN2LMNANPC1
SCHEMBL25753458 0.78 MAPT (0.55) MAOBMAPTSMN1; SMN2LMNANPC1
SCHEMBL25753461 0.77 PTGS2 (0.49) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL25753457 0.76 MAOB (0.53) MAOBMAPTSMN1; SMN2LMNANPC1
SCHEMBL25753466 0.76 MAPT (0.55) MAPTSMN1; SMN2LMNARAB9AALDH1A1
SCHEMBL26248943 0.74 MAPT (0.54) MAOBMAPTSMN1; SMN2LMNANPC1
SCHEMBL28497749 0.73 JAK2 (0.56) MAOBMAPTLMNARAB9AMAPK1
SCHEMBL26248945 0.73 MAOA (0.52) MAOBMAPTSMN1; SMN2LMNANPC1
SCHEMBL25753656 0.73 KDM4E (0.51) MAPTSMN1; SMN2LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-09-07 US disclosed
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-09-07 US disclosed
EP-4205741-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) 2023-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277508-A1 USE OF COMPOUND AS CYP2E1 INHIBITOR CYP2E1, CYP11B1, CYP27A1 MAOB 857/4885MAPT 1097/4885SMN1; SMN2 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.